Kilambi News
Sunday, November 22, 2026

Compass completes first psilocybin application as Usona race tightens

Life Sciences Sunday, November 22, 2026 - Updated Nov 22, 2026 07:05

Compass Pathways completed its FDA application for COMP360 psilocybin on November 9, while an unconfirmed report says nonprofit Usona filed first for major depression.

Why it matters: The first approved classic psychedelic is now a live regulatory question, with analysts still projecting blockbuster sales for Compass despite a roughly 30 percent share fall.

Data as of PharmaVoice and BioPharma Dive reporting of November 20, 2026. Compass's November 9 application is company confirmed; Usona's reported filing is unconfirmed, Usona declined to comment, and that element is flagged in the body.

The race to win the first Food and Drug Administration approval for a classic psychedelic has become a two company contest. Compass Pathways, long considered the field’s leader, completed its approval application on November 9 for COMP360, its psilocybin candidate for treatment resistant depression. Days earlier, an industry analyst reported that the nonprofit Usona Institute had already filed its own psilocybin application, in major depressive disorder. Usona has not confirmed the submission and told PharmaVoice it is not providing comments at this time.

The reported Usona filing caught investors by surprise, according to analysts at Stifel, and Compass shares dropped by around 30 percent following the news. Usona’s position is unusual: it received a voucher for speedier review under the Commissioner’s National Priority Voucher Program in April, but it has yet to publicly release data from its Phase 3 study, and approvals are ordinarily supported by two pivotal trials. Its stated mission is to supply psilocybin at low cost for broad access.

Compass, by contrast, has published longer term data, releasing 52 week durability results in September, and holds patents on COMP360. Analyst Emma Wille at Citeline estimated a list price of about $34,000 per year for COMP360 in an August forecast, based on two to four doses a year. Treatment requires multiple hours in a clinic with trained professionals, which shapes both the cost and the delivery model. Multiple analysts still project blockbuster sales for Compass even if Usona reaches the market first, because the two products target different forms of depression and Compass has the commercial infrastructure Usona lacks.

No psychedelic is approved yet, and the unconfirmed half of this story should be read as such. What is confirmed is that the first completed psilocybin application is now with the FDA, and that a nonprofit with unreleased pivotal data may be ahead of the company the market had priced as the certain winner.

Sources

  1. Will the first approved psychedelic become a blockbuster? - BioPharma Dive (PharmaVoice) - 2026-11-20